Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (CBAABC), where A=mindfulness meditation, B=yoga, and C=brisk walking.

Participants will have access to all 30-minute videos for A=mindfulness meditation, B=yoga, and C=brisk walking, during the 12-week phase of the study. They will be limited to 12 total views per stress management technique.

At the end of the intervention in the personalized trial arms (Arm 1 & Arm 2), personalized trial data will be used to identify which intervention (mindfulness, yoga, or walking) was most effective at reducing stress. This recommendation will be presented in a personalized report sent after completion of the intervention. The number of participants in the personalized trial arms who select this recommended intervention during follow-up relative to the total number of participants in Arms 1 & 2 will be presented as a count of participants/percentage, with a higher count of participants/percentage indicating greater levels of agreement.

The SUS is a validated 10-item questionnaire that asks users to score each item on a Likert scale from Strongly Disagree (rating of 1) to Strongly Agree (rating of 5). The SUS has a minimum score of 0 and a maximum score of 40. The SUS will be presented to the participant as addressing the ease of use, complexity, consistency of the Personalized Trials system as a whole, from recruitment to receipt of the report.

Odd items are scored by subtracting one from the user response. Even-numbered items are scored by subtracting the user responses from 5. This scales all values from 0 to 4 (with four being the most positive response). Converted responses are summed and multiplied by 2.5. This converts the range of possible values to a composite measure from 0 to 100, reported below. Participant SUS scores will be averaged together and an overall mean will be reported with standard deviation. Higher scored values correlate to a more usable system, and therefore a better outcome.

Participants will rate their satisfaction with the Trial overall and with individual elements of the trial in a satisfaction survey. Satisfaction items are not part of an already existing scale but were developed to assess participant satisfaction with specific elements of the current study and the trial overall. Participants will rate their satisfaction on a scale of 1 to 5, with higher numbers indicating greater levels of satisfaction. Means and standard deviations will be reported for each element of satisfaction.

Stress will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their stress on a scale of 0 (low) to 10 (high). Levels of EMA stress will be aggregated within the baseline assessment period and in each of the treatment periods (yoga, meditation, guided walking), and then averaged across each treatment period, to generate an overall mean and standard deviation for each period. Changes in EMA stress from baseline to each treatment period will be evaluated using Generalized Linear Mixed Model analyses.

Fatigue will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their stress on a scale of 0 (low) to 10 (high). Levels of EMA fatigue will be aggregated within the baseline assessment period and in each of the treatment periods (yoga, meditation, guided walking), and then averaged across each treatment period, to generate an overall mean and standard deviation for each period. Changes in EMA fatigue from baseline to each treatment period will be evaluated using Generalized Linear Mixed Model analyses.

Pain will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their stress on a scale of 0 (low) to 10 (high). Levels of EMA pain will be aggregated within the baseline assessment period and in each of the treatment periods (yoga, meditation, guided walking), and then averaged across each treatment period, to generate an overall mean and standard deviation for each period. Changes in EMA pain from baseline to each treatment period will be evaluated using Generalized Linear Mixed Model analyses.

Mood will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their stress on a scale of 0 (low) to 10 (high). Levels of EMA mood will be aggregated within the baseline assessment period and in each of the treatment periods (yoga, meditation, guided walking), and then averaged across each treatment period, to generate an overall mean and standard deviation for each period. Changes in EMA mood from baseline to each treatment period will be evaluated using Generalized Linear Mixed Model analyses.

Concentration will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their stress on a scale of 0 (low) to 10 (high). Levels of EMA Concentration will be aggregated within the baseline assessment period and in each of the treatment periods (yoga, meditation, guided walking), and then averaged across each treatment period, to generate an overall mean and standard deviation for each period. Changes in EMA Concentration from baseline to each treatment period will be evaluated using Generalized Linear Mixed Model analyses.

Confidence will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their stress on a scale of 0 (low) to 10 (high). Levels of EMA Confidence will be aggregated within the baseline assessment period and in each of the treatment periods (yoga, meditation, guided walking), and then averaged across each treatment period, to generate an overall mean and standard deviation for each period. Changes in EMA Confidence from baseline to each treatment period will be evaluated using Generalized Linear Mixed Model analyses.

Nightly sleep duration will be assessed by a Fitbit device. Sleep duration will be aggregated within the baseline assessment period and in each of the treatment periods (yoga, meditation, guided walking) to generate an overall mean and standard deviation for each period. Mean sleep duration will be compared to baseline using three paired-samples t-tests (yoga vs baseline, meditation vs baseline, guided walking vs baseline). Sleep duration values over the course of the study will also be evaluated using Generalized Linear Mixed Model analyses.

For each participant of the proportion of surveys measures completed (both daily and weekly surveys) will be calculated. Completion rates across all participants will be reported with means and standard deviations.

For each participant of the proportion of EMA measures completed will be calculated. Completion rates across all participants will be reported with means and standard deviations.

For each participant, the proportion of days where the Fitbit device was worn will be calculated. Completion rates across all participants will be reported with means and standard deviations.

For each participant, the average days of participant-observed sleep data, defined as recorded sleep and wake cycles, will be calculated across all participants with means and standard deviations.

For each participant, the intervention adherence rate, defined as unique video views of the appropriate recorded intervention during the assigned interventions, will be calculated and reported across all applicable individuals with means and standard deviations.

For each participant, the intervention adherence rate, defined as unique video views of the appropriate recorded intervention during the assigned interventions, will be calculated and reported across all applicable individuals with means and standard deviations.

For each participant, the follow-up period adherence rate, defined as unique video views of the appropriate recorded intervention during the assigned follow-up period, will be calculated and reported across all individuals with means and standard deviations.

After completion of the trial, a random sample of 10% of participants from each arm will be asked to participate in 60-minute qualitative interviews to discuss their experiences. Descriptive content from these recorded and transcribed interviews will be analyzed and reported.

Participants in Arm 2 will receive a Personalized Trial of the 3 stress management interventions in a CBAABC treatment order, where A=mindfulness meditation, B=yoga, and C=brisk walking. Participants in this arm will be prompted to complete 30-minute stress management sessions during applicable treatment weeks. A link to the stress management video will be delivered via text 3 times per week to the participant during applicable intervention periods in the personalized trial arms. Participants will be limited to three views of the study-provided stress management content each week.

Personalized Trial CBAABC: Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (CBAABC), where A=mindfulness meditation, B=yoga, and C=brisk walking.

Participants in Arm 3 will receive Standard Care of the 3 stress management techniques (mindfulness meditation, yoga, and brisk walking). Participants will receive access to the same number of views of the mindfulness meditation, yoga, and brisk walking content given to participants randomized in Arm 1 and Arm 2. However, they will not be prompted to complete any session according to a randomization sequence. A link to the stress management video will be delivered via text 1 time per week to the participant. Participants will be limited to 36 total views of study-provided stress management content (12 total views per stress management technique).

Stress Management Techniques with No Randomization Sequence (or order): Participants will have access to all 30-minute videos for A=mindfulness meditation, B=yoga, and C=brisk walking, during the 12-week phase of the study. They will be limited to 12 total views per stress management technique.

Total of all reporting groups

Weekly perceived stress will be assessed with the 10-item Perceived Stress Scale (PSS-10), modified to be delivered to assess the prior week rather than the prior month. The minimum total score possible is 0 and the maximum total score possible is 40. Higher values represent higher level of stress. Levels of weekly perceived stress will be aggregated within the baseline assessment period and during the follow-up period to generate an overall mean and standard deviation for each period. The change in weekly perceived stress between baseline and follow-up will be examined using Generalized Linear Mixed Model analyses.

N=69 (65.1%) of Personalized Trial participants and n=60 (56.6%) Standard Care participants had sufficient survey data for primary outcome analyses.

Arms 1&2 combined because the 2 treatment orders had intervention orders counterbalanced to remove potential issues (e.g. everyone receiving massage first). Arms were designed to be combined to ensure comparisons benefit from counter-balancing of treatment orders. There is no meaningful reason to separate Arms 1&2 from an analysis perspective.

At the end of the intervention in the personalized trial arms (Arm 1 & Arm 2), personalized trial data will be used to identify which intervention (mindfulness, yoga, or walking) was most effective at reducing stress. This recommendation will be presented in a personalized report sent after completion of the intervention. The number of participants in the personalized trial arms who select this recommended intervention during follow-up relative to the total number of participants in Arms 1 & 2 will be presented as a count of participants/percentage, with a higher count of participants/percentage indicating greater levels of agreement.

Of the n=53 participants randomized to Arm 1 (Personalized Trial ABCCBA), n=42 (79.2%) selected an intervention. Of the n=53 participants randomized to Arm 2 (Personalized Trial CBAABC), n=39 (73.6%) selected an intervention to complete during the follow-up period.

The SUS is a validated 10-item questionnaire that asks users to score each item on a Likert scale from Strongly Disagree (rating of 1) to Strongly Agree (rating of 5). The SUS has a minimum score of 0 and a maximum score of 40. The SUS will be presented to the participant as addressing the ease of use, complexity, consistency of the Personalized Trials system as a whole, from recruitment to receipt of the report.

Odd items are scored by subtracting one from the user response. Even-numbered items are scored by subtracting the user responses from 5. This scales all values from 0 to 4 (with four being the most positive response). Converted responses are summed and multiplied by 2.5. This converts the range of possible values to a composite measure from 0 to 100, reported below. Participant SUS scores will be averaged together and an overall mean will be reported with standard deviation. Higher scored values correlate to a more usable system, and therefore a better outcome.

Of the n=212 participants who were randomized into the trial and received the System Usability Scale (SUS), n=155 (73.1%) completed the survey.

Arms 1&2 combined because the 2 treatment orders had intervention orders counterbalanced to remove potential issues (e.g. everyone receiving massage first). Arms were designed to be combined to ensure comparisons benefit from counter-balancing of treatment orders. There is no meaningful reason to separate Arms 1&2 from an analysis perspective.

Participants will rate their satisfaction with the Trial overall and with individual elements of the trial in a satisfaction survey. Satisfaction items are not part of an already existing scale but were developed to assess participant satisfaction with specific elements of the current study and the trial overall. Participants will rate their satisfaction on a scale of 1 to 5, with higher numbers indicating greater levels of satisfaction. Means and standard deviations will be reported for each element of satisfaction.

Of the n=212 participants who were randomized into the trial and received the trial satisfaction survey, n=155 (73.1%) completed the survey.

Arms 1&2 combined because the 2 treatment orders had intervention orders counterbalanced to remove potential issues (e.g. everyone receiving massage first). Arms were designed to be combined to ensure comparisons benefit from counter-balancing of treatment orders. There is no meaningful reason to separate Arms 1&2 from an analysis perspective.

Stress will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their stress on a scale of 0 (low) to 10 (high). Levels of EMA stress will be aggregated within the baseline assessment period and in each of the treatment periods (yoga, meditation, guided walking), and then averaged across each treatment period, to generate an overall mean and standard deviation for each period. Changes in EMA stress from baseline to each treatment period will be evaluated using Generalized Linear Mixed Model analyses.

n=97 (91.5%), n=99 (93.4%), n=96 (90.6%) of Personalized Trial participants had EMA data during mindfulness, yoga, & walking, respectively, for analyses.

Pre-specified by Statistical Analysis Plan to report for the 3 Treatment Periods in the Personalized Trial arm (i.e. not Standard Care Arm) only.

Fatigue will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their stress on a scale of 0 (low) to 10 (high). Levels of EMA fatigue will be aggregated within the baseline assessment period and in each of the treatment periods (yoga, meditation, guided walking), and then averaged across each treatment period, to generate an overall mean and standard deviation for each period. Changes in EMA fatigue from baseline to each treatment period will be evaluated using Generalized Linear Mixed Model analyses.

n=97 (91.5%), n=99 (93.4%), n=96 (90.6%) of Personalized Trial participants had EMA data during mindfulness, yoga, & walking, respectively, for analyses.

Pre-specified by Statistical Analysis Plan to report for the 3 Treatment Periods in the Personalized Trial arm (i.e. not Standard Care Arm) only.

Pain will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their stress on a scale of 0 (low) to 10 (high). Levels of EMA pain will be aggregated within the baseline assessment period and in each of the treatment periods (yoga, meditation, guided walking), and then averaged across each treatment period, to generate an overall mean and standard deviation for each period. Changes in EMA pain from baseline to each treatment period will be evaluated using Generalized Linear Mixed Model analyses.

n=97 (91.5%), n=99 (93.4%), n=96 (90.6%) of Personalized Trial participants had EMA data during mindfulness, yoga, & walking, respectively, for analyses.

Pre-specified by Statistical Analysis Plan to report for the 3 Treatment Periods in the Personalized Trial arm (i.e. not Standard Care Arm) only.

Mood will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their stress on a scale of 0 (low) to 10 (high). Levels of EMA mood will be aggregated within the baseline assessment period and in each of the treatment periods (yoga, meditation, guided walking), and then averaged across each treatment period, to generate an overall mean and standard deviation for each period. Changes in EMA mood from baseline to each treatment period will be evaluated using Generalized Linear Mixed Model analyses.

n=97 (91.5%), n=99 (93.4%), n=96 (90.6%) of Personalized Trial participants had EMA data during mindfulness, yoga, & walking, respectively, for analyses.

Pre-specified by Statistical Analysis Plan to report for the 3 Treatment Periods in the Personalized Trial arm (i.e. not Standard Care Arm) only.

Concentration will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their stress on a scale of 0 (low) to 10 (high). Levels of EMA Concentration will be aggregated within the baseline assessment period and in each of the treatment periods (yoga, meditation, guided walking), and then averaged across each treatment period, to generate an overall mean and standard deviation for each period. Changes in EMA Concentration from baseline to each treatment period will be evaluated using Generalized Linear Mixed Model analyses.

n=97 (91.5%), n=99 (93.4%), n=96 (90.6%) of Personalized Trial participants had EMA data during mindfulness, yoga, & walking, respectively, for analyses.

Pre-specified by Statistical Analysis Plan to report for the 3 Treatment Periods in the Personalized Trial arm (i.e. not Standard Care Arm) only.

Confidence will be assessed via 3 daily text message prompts sent at random times throughout the day asking individuals to rate their stress on a scale of 0 (low) to 10 (high). Levels of EMA Confidence will be aggregated within the baseline assessment period and in each of the treatment periods (yoga, meditation, guided walking), and then averaged across each treatment period, to generate an overall mean and standard deviation for each period. Changes in EMA Confidence from baseline to each treatment period will be evaluated using Generalized Linear Mixed Model analyses.

n=97 (91.5%), n=99 (93.4%), n=96 (90.6%) of Personalized Trial participants had EMA data during mindfulness, yoga, & walking, respectively, for analyses.

Pre-specified by Statistical Analysis Plan to report for the 3 Treatment Periods in the Personalized Trial arm (i.e. not Standard Care Arm) only.

Daily step counts will be assessed by a Fitbit device. Daily step counts will be aggregated within the baseline assessment period and in each of the treatment periods (yoga, meditation, guided walking) to generate an overall mean and standard deviation for each period. Mean daily steps will be compared to baseline using three paired-samples t-tests (yoga vs baseline, meditation vs baseline, guided walking vs baseline). Daily steps values over the course of the study will also be evaluated using Generalized Linear Mixed Model analyses.

Nightly sleep duration will be assessed by a Fitbit device. Sleep duration will be aggregated within the baseline assessment period and in each of the treatment periods (yoga, meditation, guided walking) to generate an overall mean and standard deviation for each period. Mean sleep duration will be compared to baseline using three paired-samples t-tests (yoga vs baseline, meditation vs baseline, guided walking vs baseline). Sleep duration values over the course of the study will also be evaluated using Generalized Linear Mixed Model analyses.

For each participant of the proportion of surveys measures completed (both daily and weekly surveys) will be calculated. Completion rates across all participants will be reported with means and standard deviations.

For each participant of the proportion of EMA measures completed will be calculated. Completion rates across all participants will be reported with means and standard deviations.

For each participant, the proportion of days where the Fitbit device was worn will be calculated. Completion rates across all participants will be reported with means and standard deviations.

For each participant, the average days of participant-observed sleep data, defined as recorded sleep and wake cycles, will be calculated across all participants with means and standard deviations.

For each participant, the intervention adherence rate, defined as unique video views of the appropriate recorded intervention during the assigned interventions, will be calculated and reported across all applicable individuals with means and standard deviations.

For each participant, the intervention adherence rate, defined as unique video views of the appropriate recorded intervention during the assigned interventions, will be calculated and reported across all applicable individuals with means and standard deviations.

For each participant, the follow-up period adherence rate, defined as unique video views of the appropriate recorded intervention during the assigned follow-up period, will be calculated and reported across all individuals with means and standard deviations.

After completion of the trial, a random sample of 10% of participants from each arm will be asked to participate in 60-minute qualitative interviews to discuss their experiences. Descriptive content from these recorded and transcribed interviews will be analyzed and reported.

Yoga (Intervention B) was delivered to participants in the Personalized Trials arms as part of their ABCCBA and CBAABC intervention sequences. Participants were asked to complete virtual yoga sessions via link to an online video 3 times per week in 2-week blocks.

In the Standard Care arm, participants were provided all 3 interventions including yoga (Intervention B) to complete up to 12 times each.

Walking (Intervention C) was delivered to participants in the Personalized Trials arms as part of their ABCCBA and CBAABC intervention sequences. Participants were asked to complete virtual walking sessions via link to an online video 3 times per week in 2-week blocks.

In the Standard Care arm, participants were provided all 3 interventions including walking (Intervention C) to complete up to 12 times each.

Participants in Standard Care (Arm 3) had access to complete all 3 interventions (mindfulness mediation [A], yoga [B], walking [C]) simultaneously throughout their intervention period.

During Weeks 16 and 17 of the trial, participants underwent a 2-week observational period where no interventions were delivered but participant data was monitored.